Predicting the success of the entire drug discovery process using an evidence-based approach at the start of development…
You now have access to all the content in the PAREXEL Access Hub. We look forward to engaging with you.
We will be in touch shortly.
Please complete our registration form to continue.
Addressing evidence generation in a phase-specific manner provides mutually reinforcing benefits: trials contribute to the value argument and the value data inform the design of the trials. In this way, utilizing the best available secondary research to inform primary research can reduce the risk of regulatory and reimbursement rejections.
A phase-dependent approach has potential to cut costs by avoiding investing in riskier assets, utilizing secondary evidence for multiple assets (thereby using resources more efficiently), and creating payer value while simultaneously meeting regulatory requirements.
The best way to plan evidence generation for the value story is from the beginning. But if you didn’t do that already, the sooner you start the better.
In general, APs in all three regions offer the opportunity for shorter clinical development and/or review times, meaning…
Regulatory & Payer Submissions